Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARNA
  • CUSIP: 04004710
  • Web:
  • Market Cap: $773.4 million
  • Outstanding Shares: 31,743,000
Average Prices:
  • 50 Day Moving Avg: $17.89
  • 200 Day Moving Avg: $15.11
  • 52 Week Range: $11.30 - $27.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.09
  • P/E Growth: 0.38
Sales & Book Value:
  • Annual Revenue: $120.75 million
  • Price / Sales: 6.40
  • Book Value: $0.84 per share
  • Price / Book: 28.99
  • EBIDTA: $18.42 million
  • Net Margins: -19.07%
  • Return on Equity: -108.77%
  • Return on Assets: -12.50%
  • Debt-to-Equity Ratio: 2.28%
  • Current Ratio: 1.85%
  • Quick Ratio: 1.71%
  • Average Volume: 974,525 shs.
  • Beta: 1.3
  • Short Ratio: 2.07
Frequently Asked Questions for Arena Pharmaceuticals (NASDAQ:ARNA)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.82) by $0.08. The firm earned $6.60 million during the quarter, compared to analyst estimates of $4.84 million. Arena Pharmaceuticals had a negative return on equity of 108.77% and a negative net margin of 19.07%. The company's revenue for the quarter was down 33.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.90) earnings per share. View Arena Pharmaceuticals' Earnings History.

When will Arena Pharmaceuticals make its next earnings announcement?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Arena Pharmaceuticals.

Where is Arena Pharmaceuticals' stock going? Where will Arena Pharmaceuticals' stock price be in 2017?

9 brokers have issued twelve-month price objectives for Arena Pharmaceuticals' stock. Their forecasts range from $19.00 to $60.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $38.83 in the next year. View Analyst Ratings for Arena Pharmaceuticals.

What are analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "We continue to view Phase 2 data as about as good as it gets. Despite facing comparisons with Phase 2 data for a drug, selexipag, that benefited from trial idiosyncrasies (subject randomization imbalances), the improvement in pulmonary vascular resistance (PVR) associated with treatment in the ralinepag Phase 2 trial (-30% vs. placebo and -20% vs. baseline) was at the high end of a range of effects noted to us by a physician knowledgeable in the care of patients with PAH and the development of therapies for it." (7/17/2017)
  • 2. According to Zacks Investment Research, "Arena received a boost with the launch of Belviq XR, a once-daily, extended-release formulation of its only marketed drug, Belviq, in October 2016. Though sales of Belviq have been lackluster so far, the company partnership agreements and efforts to improve Belviq’s performance is impressive. We are encouraged by the company’s cost reduction initiatives to streamline the organization to support its development programs. Moreover, the company’s decision to shift its priorities to its proprietary clinical-stage pipeline is also encouraging. The company recently announced positive results on its PAH candidate, ralinepeg. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates that are still several years from commercialization. Moreover, competition remains intense in the obesity market which has both branded and generic players." (7/4/2017)
  • 3. FBR & Co analysts commented, "We are initiating coverage of Arena Pharmaceuticals, Inc. (ARNA) with an Outperform rating and a 12-month price target of $6 per share. Historically, ARNA focused on obesity with its one approved drug, Belviq (lorcaserin). However, given the company’s expertise in discovery and drug development targeting G protein- coupled receptors (GPCRs), it is now primarily focused on advancing the pipeline with (1) etrasimod (APD334), a S1P receptor modulator for the potential treatment of ulcerative colitis (UC); (2) ralinepag, a prostacyclin receptor (PGI2) agonist for the potential treatment of pulmonary arterial hypertension (PAH); and (3) APD371, a cannabinoid receptor 2 (CB2) agonist in development for GI pain associated with Crohn’s disease." (9/15/2016)

Are investors shorting Arena Pharmaceuticals?

Arena Pharmaceuticals saw a increase in short interest in the month of July. As of July 14th, there was short interest totalling 2,089,884 shares, an increase of 106.0% from the June 30th total of 1,014,507 shares. Based on an average daily volume of 4,054,761 shares, the days-to-cover ratio is presently 0.5 days. Currently, 6.6% of the shares of the stock are sold short.

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:

  • Amit D. Munshi, President, Chief Executive Officer, Director
  • Kevin R. Lind, Chief Financial Officer, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
  • Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary
  • Vincent E. Aurentz, Executive Vice President and Chief Business Officer
  • Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer
  • Maurice J. Mezzino, Senior Vice President - Corporate Development
  • Tina Susan Nova Ph.D., Lead Independent Director
  • Donald D. Belcher, Director
  • Jayson Dallas M.D., Director
  • Oliver S. Fetzer Ph.D., Director

How do I buy Arena Pharmaceuticals stock?

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $24.35.

MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $38.83 (59.48% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/17/2017Cantor FitzgeraldReiterated RatingOverweight$37.00LowView Rating Details
7/12/2017Wells Fargo & CompanyReiterated RatingMarket Perform$15.00 -> $19.00MediumView Rating Details
7/11/2017Citigroup Inc.Boost Price TargetBuy -> Buy$23.00 -> $37.00LowView Rating Details
7/11/2017Leerink SwannBoost Price TargetOutperform$47.00 -> $53.00HighView Rating Details
7/7/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$27.00 -> $27.00HighView Rating Details
3/16/2017FBR & CoReiterated RatingOutperform$60.00MediumView Rating Details
1/7/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
8/8/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/2/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
3/1/2016Royal Bank Of CanadaReiterated RatingSector Perform$20.00 -> $15.00N/AView Rating Details
10/28/2015WallachBeth CapitalLower Price TargetBuy$60.00 -> $40.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Earnings History by Quarter for Arena Pharmaceuticals (NASDAQ ARNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017($0.74)N/AView Earnings Details
5/9/2017Q1 2017($0.82)($0.90)$4.84 million$6.60 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.80)$1.60$14.12 million$85.40 millionViewN/AView Earnings Details
11/7/2016Q316($0.70)($0.50)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($1.00)($1.10)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($1.00)($0.90)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($1.30)($1.30)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($1.30)($1.10)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($1.40)($1.10)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($1.40)($1.00)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($1.20)($1.50)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($1.30)($0.50)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($1.10)($1.20)$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($1.00)($1.20)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.20($1.10)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($1.20)($0.80)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$1.50$1.80$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$1.10$0.90$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.30)($1.00)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($1.10)($0.70)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.80)($1.20)ViewN/AView Earnings Details
11/9/2011($1.40)($1.60)ViewN/AView Earnings Details
8/9/2011($1.50)($1.60)ViewN/AView Earnings Details
5/10/2011($2.10)($3.50)ViewN/AView Earnings Details
3/11/2011($2.20)($2.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.64)($0.64)($0.64)
Q3 20171($0.68)($0.68)($0.68)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)


Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Ownership Percentage: 1.88%
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Amit MunshiInsiderBuy25,000$1.19$29,750.00View SEC Filing  
4/26/2017Amit MunshiInsiderBuy50,000$1.41$70,500.00View SEC Filing  
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Arena Pharmaceuticals (NASDAQ:ARNA)
Latest Headlines for Arena Pharmaceuticals (NASDAQ:ARNA)
DateHeadline logoTop Ranked Momentum Stocks to Buy for July 24th - July 24 at 1:03 PM logoFY2017 EPS Estimates for Arena Pharmaceuticals, Inc. Increased by Cantor Fitzgerald (NASDAQ:ARNA) - July 21 at 11:21 AM logoArena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says - - July 17 at 4:23 PM logoArena Pharma Skyrockets on Heart Disease Data, Stock Could Still Double -Firm Says - July 17 at 4:23 PM logoArena Announces Secondary Stock Worth $150M (revised) - July 17 at 4:23 PM logoArena Pharmaceuticals, Inc. (ARNA) Stock Rating Reaffirmed by Cantor Fitzgerald - July 17 at 11:05 AM logoArena Pharmaceuticals, Inc. (ARNA) Given Consensus Recommendation of "Buy" by Brokerages - July 17 at 10:54 AM logoTop Ranked Momentum Stocks to Buy for July 14th - July 14 at 5:55 PM logoQ2 2017 EPS Estimates for Arena Pharmaceuticals, Inc. Cut by Analyst (ARNA) - July 13 at 9:18 AM logoArena Pharma Soars On Lung Disease Drug Study Results - Barron's - July 12 at 9:33 PM logoBUZZ-US STOCKS ON THE MOVE-Halcon Resources, Getty Realty, Arena Pharma - Nasdaq - July 12 at 9:33 PM logoArena Pharmaceuticals Announces Pricing of Public Offering of Common Stock - PR Newswire (press release) - July 12 at 9:33 PM logoInvestors Draw Blood In Arena - Seeking Alpha - July 12 at 9:33 PM logoE*Trade Financial, Statoil, Arena Pharmaceuticals, Johnson & Johnson and United Therapeutics highlighted as Zacks Bull and Bear of the Day - July 12 at 4:32 PM logoArena Announces Secondary Stock Offering of 150M Shares - July 12 at 4:32 PM logoArena Pharmaceuticals, Inc. (ARNA) Receives Market Perform Rating from Wells Fargo & Company - July 12 at 10:05 AM logoArena Pharma Soars On Lung Disease Drug Study Results - July 12 at 1:43 AM logoArena's Ralinepag Positive in Phase II PAH Study, Shares Up - July 12 at 1:43 AM logoA Glimpse Into Two Climbing Biotechs: Arena Pharmaceuticals, Inc. (ARNA) and Ocular Therapeutix Inc (OCUL) - July 12 at 1:42 AM logoHere's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today - July 12 at 1:42 AM logoArena Pharma shares retreat slightly on secondary share offering - July 12 at 1:42 AM logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Price Target Increased to $37.00 by Analysts at Citigroup Inc. - July 11 at 5:26 PM logoUS STOCKS-Wall St partly recovers after falling on Trump Jr emails - Nasdaq - July 11 at 3:38 PM logoWhy Arena Is Taking Center Stage Today - Benzinga - July 11 at 3:38 PM logoBUZZ-U.S. STOCKS ON THE MOVE-Halcon Resources, Arena ... - Nasdaq - July 11 at 3:38 PM logoArena Pharmaceuticals stock skyrockets on positive hypertension-drug study - MarketWatch - July 11 at 3:38 PM logoETFs with exposure to Arena Pharmaceuticals, Inc. : July 11, 2017 - July 11 at 3:38 PM logoLeerink Swann Boosts Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Price Target to $53.00 - July 11 at 1:04 PM logoWhy Arena Is Taking Center Stage Today - July 11 at 12:55 PM logoWhy Arena Pharmaceuticals Stock Is Bolting Higher Today - July 11 at 9:52 AM logo3 Stocks to Watch on Tuesday: Snap Inc (SNAP), Barracuda Networks Inc (CUDA) and Arena Pharmaceuticals, Inc. (ARNA) - July 11 at 8:01 AM logoArena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension - July 10 at 9:05 PM logoArena's heart-lung drug meets main goal in mid-stage study - July 10 at 9:05 PM logoArena Pharmaceuticals stock skyrockets on positive hypertension-drug study - July 10 at 9:05 PM logoBiotech Movers: Alexion, Arena, Novavax - - July 8 at 3:44 PM logoArena Upgraded, Analyst Sees 44% Upside - Benzinga - July 8 at 3:44 PM logoArena Upgraded, Analyst Sees 44% Upside - July 8 at 6:31 AM logoArena Pharmaceuticals, Inc. (ARNA) Stock Rating Upgraded by JMP Securities - July 8 at 12:22 AM logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Stock Rating Upgraded by BidaskClub - July 7 at 3:10 PM logoJMP Securities Upgrades Arena Pharma (ARNA) to Market Outperform - - July 7 at 5:40 AM logoThe Surprising Catalyst That Sent Arena Pharmaceuticals, Inc. Soaring 27% in June - Motley Fool - July 7 at 5:40 AM logoThe Surprising Catalyst That Sent Arena Pharmaceuticals, Inc. Soaring 27% in June - July 6 at 11:19 AM logoAre Options Traders Betting on a Big Move in Arena Pharmaceuticals (ARNA) Stock? - July 5 at 4:41 PM logoAre Options Traders Betting on a Big Move in Arena Pharmaceuticals (ARNA) Stock? - July 5 at 4:41 PM logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Earns "Overweight" Rating from Cantor Fitzgerald - July 1 at 11:16 PM logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Expected to Announce Quarterly Sales of $5.62 Million - July 1 at 9:27 AM logoArena Ends Study on Extended Release Formulation of PAH Drug - Nasdaq - June 30 at 4:09 PM logoArena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers - June 29 at 5:04 PM logoZacks: Brokerages Expect Arena Pharmaceuticals, Inc. (ARNA) to Post -$0.67 EPS - June 29 at 10:48 AM logoArena Pharmaceuticals, Inc. (ARNA) Downgraded to "Hold" at Zacks Investment Research - June 29 at 9:00 AM



Arena Pharmaceuticals (ARNA) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff